Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
Natthawadee LaokulrathMihir GudiSyed Ahmed SalahuddinAngela Phek Yoon ChongCristine DingJabed IqbalWei Qiang LeowBenjamin Yongcheng TanGary TseEmad A RakhaPuay Hoon TanPublished in: Histopathology (2024)
Human epidermal growth factor receptor 2 (HER2)-enriched breast cancer benefits significantly from anti-HER2 targeted therapies. This highlights the critical need for precise HER2 immunohistochemistry (IHC) interpretation serving as a triage tool for selecting patients for anti-HER2 regimens. Recently, the emerging eligibility of patients with HER2-low breast cancers for a novel HER2-targeted antibody-drug conjugate (T-DXd) adds challenges to HER2 IHC scoring interpretation, notably in the 0-1+ range, which shows high interobserver and interlaboratory staining platform variability. In this review, we navigate evolving challenges and suggest practical recommendations for HER2 IHC interpretation.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- end stage renal disease
- emergency department
- induced pluripotent stem cells
- ejection fraction
- newly diagnosed
- primary care
- healthcare
- pluripotent stem cells
- prognostic factors
- cancer therapy
- chronic kidney disease
- high throughput
- drug delivery
- young adults
- single cell